Ontology highlight
ABSTRACT: Background
Non-ischemic dilated cardiomyopathy (NIDCM) responds variably to intramyocardial injection of mesenchymal stem cells (MSCs). We hypothesized that NIDCM genotype may influence responsiveness to MSC therapy and performed genotyping on all patients in the POSEIDON-DCM trial.Methods
POSEIDON-DCM patients (n = 34) underwent genetic sequence analysis and deletion/duplication testing. The results were classified as positive for pathological variants (PV+; n = 8), negative for any variants (V-; n = 6), or as variants of uncertain significance (VUS; n = 20). All outcomes of therapy were analysed for each category of genetic results.Findings
The 3 groups were indistinguishable at baseline with regard to ejection fraction (EF), demographics, medication use, or funct
SUBMITTER: Rieger AC
PROVIDER: S-EPMC6838383 | biostudies-literature | 2019 Oct
REPOSITORIES: biostudies-literature